Jefferies Analysts Issue Mixed Ratings on Pharma Giants Novartis and Sanofi
核心洞察
Jefferies (搜索) analyst James Vane maintained a Hold rating on Novartis AG with a CHF110.00 price target, while the company reported Q1 revenue of CHF12.83 billion and net profit of CHF3.09 billion.
Jefferies (搜索) analyst Michael Leuchten reaffirmed a Buy rating on Sanofi with a €100.00 price target, with Deutsche Bank (搜索) also maintaining a Buy rating at the same price target.
Novartis holds an analyst consensus of Moderate Buy with a price target consensus of CHF121.83, based on TipRanks data.
Jefferies (搜索) analysts have issued updated ratings on two major European pharmaceutical companies, offering divergent outlooks on Novartis AG and Sanofi.
Novartis: Hold Rating Maintained
Jefferies (搜索) analyst James Vane maintained a Hold rating on Novartis AG, setting a price target of CHF110.00. According to TipRanks data, Vane is ranked #10,593 out of 12,227 analysts tracked by the platform.
Novartis AG currently holds an analyst consensus of Moderate Buy, with a price target consensus of CHF121.83, suggesting some upside potential from current levels despite the Hold rating from Jefferies (搜索).
The Swiss pharmaceutical giant reported quarterly revenue of CHF12.83 billion for the quarter ending March 31, alongside a net profit of CHF3.09 billion. These figures represent a decline compared to the same period last year, when the company posted revenue of CHF13.62 billion and a net profit of CHF3.61 billion.
Sanofi: Buy Rating Reaffirmed
In a separate report, Jefferies (搜索) analyst Michael Leuchten maintained a Buy rating on Sanofi, with a price target of €100.00. Leuchten is ranked #11,254 out of 12,227 analysts on TipRanks.
The bullish stance on Sanofi was echoed by Deutsche Bank (搜索), which also maintained a Buy rating on the stock with an identical €100.00 price target in a report released on May 28.
Sanofi shares have traded within a one-year range of €71.73 to €91.15, with the company maintaining an average trading volume of 2.49 million shares.
The contrasting ratings reflect differing assessments of the two pharmaceutical companies' near-term prospects, with Sanofi garnering more optimistic analyst sentiment compared to the more cautious outlook on Novartis.